CLDI — Calidi Biotherapeutics, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1855485 ·
Last close
$0.56
Market Cap
$2.06M
52W High
$24.80
52W Low
$0.55
ADV30
42,469
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,150,000 | -4,160,000 | 7,204,000 | 4,071,000 | 4,071,000 |
| Mar 2026 | 0 | — | -4,187,000 | -4,108,000 | 9,591,000 | 6,631,000 | 4,656,000 |
| Dec 2025 | 0 | — | -4,466,000 | -4,056,000 | 8,857,000 | 5,600,000 | 5,098,000 |
| Sep 2025 | 0 | — | -5,048,000 | -5,149,000 | 14,029,000 | 10,375,000 | 6,831,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,751,000
Investing CF
$-144,000
Financing CF
$16,808,000
CapEx
$-94,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-76.93
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-149,889,000
Inventory
—
Receivables
$266,000
ST Investments
—
EBIT TTM
$-17,335,000
Pretax Income TTM
$-17,491,000
Interest Exp TTM
$156,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,190,000 | -19,906,000 | 8,857,000 | 5,098,000 | 3,759,000 | -21,293,000 |
| Dec 2024 | 0 | -21,595,000 | -22,143,000 | 14,182,000 | 12,214,000 | 1,534,000 | -19,694,000 |
| Dec 2023 | 0 | -26,107,000 | -29,216,000 | 10,019,000 | 18,254,000 | -8,235,000 | -26,983,000 |
| Dec 2022 | 45,000 | -23,128,000 | -25,427,000 | 2,597,000 | 53,037,000 | -50,440,000 | -13,214,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$-27,402,000
NetIncome TTM
$-17,397,000
OpCashFlow TTM
—
Assets (Latest)
$7,204,000
Forward EPS
$-0.90
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VIVS | VivoSim Labs, INC. | $2.44M | $0.12 | — |
| ABPO | Abpro Holdings, Inc. | $2.65M | $0.45 | — |
| BCAB | BioAtla, Inc. | $3.00M | $1.80 | — |
| SNTI | Senti Biosciences Holdings, Inc. | $3.02M | $0.10 | — |
| AGTX | Agentix Corp. | $1.35M | $0.03 | — |
News headlines (Yahoo Finance, 1h cache)
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-13 22:03 · Yahoo
Calidi Biotherapeutics Presented New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026, Including Highlighting the Potential of its RedTail Gene Medicine Platform to Turn Tumors
2026-10-27 12:00 · Yahoo
Calidi Biotherapeutics to Present New CLD-401 Data and In Situ TCE Platform Advances at the ESMO Congress 2026
2026-10-19 12:00 · Yahoo
Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
2026-09-25 21:00 · Yahoo
Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-13 20:30 · Yahoo
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conferen
2026-07-27 12:00 · Yahoo
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
2026-07-20 20:30 · Yahoo
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors
2026-06-23 12:00 · Yahoo
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston
2026-05-13 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.